Is ACTU or VTVT more profitable?

vTv Therapeutics' return on equity of -6.27% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Actuate Therapeutics N/A -346.19% -178.40% vTv Therapeutics N/A -6.27% -5.06%

Which has higher earnings & valuation, AARD or ACTU?

Aardvark Therapeutics is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aardvark Therapeutics N/A N/A -$57.59M -$3.21 N/A Actuate Therapeutics N/A N/A -$22.23M -$0.87 N/A

Is AARD or ACTU more profitable?

Aardvark Therapeutics' return on equity of -71.54% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aardvark Therapeutics N/A -71.54% -64.94% Actuate Therapeutics N/A -346.19% -178.40%

Which has preferable earnings & valuation, ACTU or VANI?

Vivani Medical is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Actuate Therapeutics N/A N/A -$22.23M -$0.87 N/A Vivani Medical N/A N/A -$26.61M -$0.35 N/A

Is ACTU or VANI more profitable?

Vivani Medical's return on equity of -191.05% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Actuate Therapeutics N/A -346.19% -178.40% Vivani Medical N/A -191.05% -70.91%

Which has higher valuation and earnings, PYPD or ACTU?

PolyPid is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PolyPid N/A N/A -$34.17M -$1.48 N/A Actuate Therapeutics N/A N/A -$22.23M -$0.87 N/A

Is PYPD or ACTU more profitable?

PolyPid's return on equity of -311.08% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets PolyPid N/A -311.08% -150.83% Actuate Therapeutics N/A -346.19% -178.40%

Which has stronger valuation and earnings, PLYX or ACTU?

Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polaryx Therapeutics N/A N/A -$8.98M -$0.08 N/A Actuate Therapeutics N/A N/A -$22.23M -$0.87 N/A

Is PLYX or ACTU more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Polaryx Therapeutics N/A N/A N/A Actuate Therapeutics N/A -346.19% -178.40%

Actuate Therapeutics (ACTU) Competitors

$1.37 +0.07 (+5.38%)

As of 09/3/2026 04:00 PM Eastern

Compare

ACTU vs. VTVT, AARD, VANI, PYPD, and PLYX

Should you buy Actuate Therapeutics stock or one of its competitors? Actuate Therapeutics's main competitors and comparable companies include vTv Therapeutics (VTVT), Aardvark Therapeutics (AARD), Vivani Medical (VANI), PolyPid (PYPD), and Polaryx Therapeutics (PLYX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Actuate Therapeutics compare to vTv Therapeutics?

Actuate Therapeutics (NASDAQ:ACTU) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

In the previous week, vTv Therapeutics had 4 more articles in the media than Actuate Therapeutics. MarketBeat recorded 4 mentions for vTv Therapeutics and 0 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 1.00 beat vTv Therapeutics' score of 0.19 indicating that Actuate Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Actuate Therapeutics	Positive
vTv Therapeutics	Neutral

Actuate Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

Actuate Therapeutics currently has a consensus target price of $10.50, suggesting a potential upside of 666.42%. vTv Therapeutics has a consensus target price of $55.83, suggesting a potential upside of 66.82%. Given Actuate Therapeutics' higher probable upside, equities research analysts plainly believe Actuate Therapeutics is more favorable than vTv Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
vTv Therapeutics	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Actuate Therapeutics has higher earnings, but lower revenue than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.87	N/A
vTv Therapeutics	$1.02M	129.29	-$26.97M	-$1.06	N/A

vTv Therapeutics' return on equity of -6.27% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-346.19%	-178.40%
vTv Therapeutics	N/A	-6.27%	-5.06%

17.5% of vTv Therapeutics shares are held by institutional investors. 58.0% of Actuate Therapeutics shares are held by company insiders. Comparatively, 6.0% of vTv Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Actuate Therapeutics and vTv Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Actuate Therapeutics compare to Aardvark Therapeutics?

Aardvark Therapeutics (NASDAQ:AARD) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

Aardvark Therapeutics' return on equity of -71.54% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-71.54%	-64.94%
Actuate Therapeutics	N/A	-346.19%	-178.40%

Aardvark Therapeutics has a beta of 3.74, meaning that its stock price is 274% more volatile than the broader market. Comparatively, Actuate Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

In the previous week, Aardvark Therapeutics had 24 more articles in the media than Actuate Therapeutics. MarketBeat recorded 24 mentions for Aardvark Therapeutics and 0 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 1.00 beat Aardvark Therapeutics' score of 0.03 indicating that Actuate Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aardvark Therapeutics	Neutral
Actuate Therapeutics	Positive

Aardvark Therapeutics currently has a consensus target price of $15.33, indicating a potential upside of 167.60%. Actuate Therapeutics has a consensus target price of $10.50, indicating a potential upside of 666.42%. Given Actuate Therapeutics' higher probable upside, analysts plainly believe Actuate Therapeutics is more favorable than Aardvark Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.42
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Aardvark Therapeutics is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.87	N/A

Summary

Aardvark Therapeutics beats Actuate Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Actuate Therapeutics compare to Vivani Medical?

Actuate Therapeutics (NASDAQ:ACTU) and Vivani Medical (NASDAQ:VANI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

Vivani Medical is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.87	N/A
Vivani Medical	N/A	N/A	-$26.61M	-$0.35	N/A

Actuate Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, Vivani Medical has a beta of 2.36, meaning that its share price is 136% more volatile than the broader market.

6.8% of Vivani Medical shares are owned by institutional investors. 58.0% of Actuate Therapeutics shares are owned by insiders. Comparatively, 53.3% of Vivani Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Vivani Medical's return on equity of -191.05% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-346.19%	-178.40%
Vivani Medical	N/A	-191.05%	-70.91%

In the previous week, Vivani Medical had 2 more articles in the media than Actuate Therapeutics. MarketBeat recorded 2 mentions for Vivani Medical and 0 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 1.00 beat Vivani Medical's score of 0.00 indicating that Actuate Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Actuate Therapeutics	Positive
Vivani Medical	Neutral

Actuate Therapeutics presently has a consensus price target of $10.50, indicating a potential upside of 666.42%. Vivani Medical has a consensus price target of $3.75, indicating a potential upside of 169.78%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Actuate Therapeutics is more favorable than Vivani Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Actuate Therapeutics and Vivani Medical tied by winning 6 of the 12 factors compared between the two stocks.

How does Actuate Therapeutics compare to PolyPid?

PolyPid (NASDAQ:PYPD) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

PolyPid's return on equity of -311.08% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-311.08%	-150.83%
Actuate Therapeutics	N/A	-346.19%	-178.40%

In the previous week, PolyPid had 1 more articles in the media than Actuate Therapeutics. MarketBeat recorded 1 mentions for PolyPid and 0 mentions for Actuate Therapeutics. PolyPid's average media sentiment score of 1.83 beat Actuate Therapeutics' score of 1.00 indicating that PolyPid is being referred to more favorably in the media.

Company	Overall Sentiment
PolyPid	Very Positive
Actuate Therapeutics	Positive

PolyPid is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.48	N/A
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.87	N/A

PolyPid presently has a consensus price target of $11.33, indicating a potential upside of 115.05%. Actuate Therapeutics has a consensus price target of $10.50, indicating a potential upside of 666.42%. Given Actuate Therapeutics' higher possible upside, analysts clearly believe Actuate Therapeutics is more favorable than PolyPid.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

PolyPid has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Comparatively, Actuate Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market.

26.5% of PolyPid shares are owned by institutional investors. 24.7% of PolyPid shares are owned by insiders. Comparatively, 58.0% of Actuate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

PolyPid beats Actuate Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Actuate Therapeutics compare to Polaryx Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.08	N/A
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.87	N/A

Polaryx Therapeutics' return on equity of 0.00% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
Actuate Therapeutics	N/A	-346.19%	-178.40%

In the previous week, Polaryx Therapeutics had 3 more articles in the media than Actuate Therapeutics. MarketBeat recorded 3 mentions for Polaryx Therapeutics and 0 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 1.00 beat Polaryx Therapeutics' score of 0.25 indicating that Actuate Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Polaryx Therapeutics	Neutral
Actuate Therapeutics	Positive

Polaryx Therapeutics presently has a consensus target price of $7.67, indicating a potential upside of 285.26%. Actuate Therapeutics has a consensus target price of $10.50, indicating a potential upside of 666.42%. Given Actuate Therapeutics' higher possible upside, analysts clearly believe Actuate Therapeutics is more favorable than Polaryx Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Polaryx Therapeutics beats Actuate Therapeutics on 7 of the 10 factors compared between the two stocks.

Get Actuate Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACTU vs. The Competition

Export

Metric	Actuate Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$31.22M	$12.24B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	-1.57	787.27	273.28	25.38
Price / Sales	N/A	753.79	613.48	92.60
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	34.25	12.33	12.89	6.14
Net Income	-$22.23M	$2.82B	$3.47B	$349.01M
7 Day Performance	-17.22%	2.60%	0.61%	-0.27%
1 Month Performance	22.32%	6.96%	5.73%	0.68%
1 Year Performance	-84.29%	9.48%	25.37%	14.84%

Actuate Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACTU Actuate Therapeutics	2.6047 of 5 stars	$1.37 +5.4%	$10.50 +666.4%	-84.1%	$31.22M	N/A	N/A	10	News Coverage Positive News Short Interest Increase Gap Up
VTVT vTv Therapeutics	2.7355 of 5 stars	$33.33 +4.3%	$55.83 +67.5%	+77.4%	$131.56M	$36.84M	N/A	9
AARD Aardvark Therapeutics	2.8675 of 5 stars	$5.92 flat	$15.33 +159.0%	-30.0%	$128.24M	N/A	N/A	18	Trending News
VANI Vivani Medical	2.6371 of 5 stars	$1.42 +4.0%	$3.75 +165.0%	+19.8%	$127.63M	N/A	N/A	20	News Coverage
PYPD PolyPid	3.2373 of 5 stars	$5.28 -1.0%	$11.33 +114.8%	+54.1%	$100.66M	N/A	N/A	80	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACTU) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Actuate Therapeutics (ACTU) Competitors

ACTU vs. VTVT, AARD, VANI, PYPD, and PLYX

How does Actuate Therapeutics compare to vTv Therapeutics?

Summary

How does Actuate Therapeutics compare to Aardvark Therapeutics?

Summary

How does Actuate Therapeutics compare to Vivani Medical?

Summary

How does Actuate Therapeutics compare to PolyPid?

Summary

How does Actuate Therapeutics compare to Polaryx Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACTU vs. The Competition

Actuate Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Actuate Therapeutics (ACTU) Competitors

ACTU vs. VTVT, AARD, VANI, PYPD, and PLYX

How does Actuate Therapeutics compare to vTv Therapeutics?

Does the media prefer ACTU or VTVT?

Which has more volatility and risk, ACTU or VTVT?

Do analysts rate ACTU or VTVT?

Which has better valuation and earnings, ACTU or VTVT?

Is ACTU or VTVT more profitable?

Do institutionals and insiders have more ownership in ACTU or VTVT?

Summary

How does Actuate Therapeutics compare to Aardvark Therapeutics?

Is AARD or ACTU more profitable?

Which has more volatility & risk, AARD or ACTU?

Does the media favor AARD or ACTU?

Do analysts prefer AARD or ACTU?

Which has higher earnings & valuation, AARD or ACTU?

Summary

How does Actuate Therapeutics compare to Vivani Medical?

Which has preferable earnings & valuation, ACTU or VANI?

Which has more risk & volatility, ACTU or VANI?

Do insiders & institutionals believe in ACTU or VANI?

Is ACTU or VANI more profitable?

Does the media prefer ACTU or VANI?

Do analysts recommend ACTU or VANI?

Summary

How does Actuate Therapeutics compare to PolyPid?

Is PYPD or ACTU more profitable?

Does the media favor PYPD or ACTU?

Which has higher valuation and earnings, PYPD or ACTU?

Do analysts recommend PYPD or ACTU?

Which has more risk & volatility, PYPD or ACTU?

Do institutionals and insiders believe in PYPD or ACTU?

Summary

How does Actuate Therapeutics compare to Polaryx Therapeutics?

Which has stronger valuation and earnings, PLYX or ACTU?

Is PLYX or ACTU more profitable?

Does the media refer more to PLYX or ACTU?

Do analysts prefer PLYX or ACTU?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACTU vs. The Competition

Actuate Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools